ABVX Share Price Performance
Recent ABVX News & Updates
No updates
ABIVAX Société Anonyme Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Sep 08, 2025
- Earnings per share (EPS)
- -2.46
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,754.30%
- Debt/Equity Ratio
- -1,584.3%
ABIVAX Société Anonyme Competitors
About ABVX
- Founded
- 2013
- Employees
- 69
- CEO
- WebsiteView website
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
French Market Performance
- 7 Days: -3.9%
- 3 Months: -3.1%
- 1 Year: 2.8%
- Year to Date: 0.7%
Over the last 7 days, the market has dropped 3.9%, driven by a decline of 7.9% in the Consumer Discretionary sector. Although the market performance has been flat over the past year. Earnings are forecast to grow by 12% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading